文献速递炎症性肠病

5-氨基水杨酸联合生物制剂或托法替布治疗溃疡性结肠炎的成本效果分析

Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis.
PubMed 文献 · Am J Gastroenterol · 2021-01-01

本研究对已升级至生物制剂或托法替布治疗的溃疡性结肠炎患者进行成本效果分析,比较继续联合5-氨基水杨酸(5-ASA)与停用5-ASA的单药方案。模型显示生物制剂/托法替布单药治疗占优(更便宜且更有效),概率敏感性分析中单药在100%情景下占优,2年平均节省24483.01美元。

要点

  • 在需生物制剂或托法替布治疗的溃疡性结肠炎患者中,继续5-ASA不具成本效果。
  • 生物制剂/托法替布单药较联合5-ASA占优,2年平均节省24483.01美元。
  • 概率敏感性分析1万次模拟中单药方案在100%情景下占优。

核心结论

  • 在需生物制剂或托法替布治疗的溃疡性结肠炎患者中,继续5-ASA治疗不是成本效果策略;停用5-ASA安全且更便宜,应推荐停用。

研究设计与样本

  • 成本效果分析,比较5-ASA联合生物制剂/托法替布与不含5-ASA的相同治疗;支付意愿阈值50000美元/质量调整生命年,并行1万次概率敏感性分析。

主要发现

  • 生物制剂/托法替布单药治疗占优(更便宜且更有效);概率敏感性分析中单药在100%情景下占优,2年平均节省24483.01美元。
  • 敏感性分析以维得利珠单抗为首个生物制剂、继以英夫利西单抗、最后托法替布时,单药仍占优。

关键数值与推荐

  • 主要结局为增量成本效果比,支付意愿阈值50000美元/质量调整生命年。
  • 概率敏感性分析采用10000次模拟。
  • 2年平均节省24483.01美元。

临床怎么用

  • 作者认为,在这些患者中停用5-ASA安全且更便宜,应推荐停用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Medications are major cost drivers in the treatment of patients with inflammatory bowel disease. Recent analyses suggest that there is no added efficacy in continuing nor harm in stopping 5-aminosalicylate (ASA) therapy in patients with inflammatory bowel disease escalated to biological therapies or tofacitinib. We assessed the cost-effectiveness of discontinuing 5-ASA therapy in patients with ulcerative colitis on biological therapies or tofacitinib, compared with continuing 5-ASA therapy. METHODS: We performed a cost-effectiveness analysis of 5-ASA with biologic therapy and tofacitinib compared with the same treatment without 5-ASA. Our primary outcome was to determine whether biologic/tofacitinib monotherapy was cost-effective compared with biologic/tofacitinib and 5-ASA combination therapy using the incremental cost-effectiveness ratio at a willingness to pay of $50,000/quality-adjusted life year. Owing to the uncertainty surrounding outcome probabilities, probabilistic sensitivity analyses with 10,000 simulations were also performed. We conducted a sensitivity analysis comparing biologic/tofacitinib and 5-ASA therapy compared with biologic/tofacitinib monotherapy, whereby vedolizumab was the first biologic used, followed by infliximab and finally tofacitinib. RESULTS: Our model shows that biologic/tofacitinib monotherapy dominates (cheaper and more effective) combination therapy of biologics/tofacitinib with 5-ASA. Probabilistic sensitivity analyses simulations resulted in biologic/tofacitinib monotherapy dominating 100% of the scenarios, with mean cost savings of $24,483.01 over 2 years. When vedolizumab was the first-line therapy in the sensitivity analysis, biologic/tofacitinib monotherapy continued to dominate the combination of 5-ASA and biologic/tofacitinib therapy. DISCUSSION: This analysis in patients with ulcerative colitis who require treatment with biologics or tofacitinib demonstrates that continuing 5-ASA therapy is not a cost-effective strategy. Discontinuation of 5-ASA therapy in these patients is safe and less expensive and should be recommended.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Shaffer SR, Huang E, Patel S, et al. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol. 2021. PMID: 32947317. doi:10.14309/ajg.0000000000000847

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。